KYTX · NASDAQ · Biotechnology

Kyverna Therapeutics (KYTX)

Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.

$7.02
vs last close−0.49 (−6.48%)

Something off on this page? Send us feedback.

Next report
Nov 11, 26
estimated · in 49 days
EPS estimate
−$0.68
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.88−$1.03−$0.97−$0.85−$0.80−$0.66−$0.63Pending
Estimate−$0.87−$1.21−$1.00−$0.97−$0.85−$0.75−$0.68−$0.68
Surprise−1.1%+14.9%+3.0%+12.4%+5.3%+12.0%+7.1%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2028$0.54
Sep 2028$0.24
Jun 2028−$0.10
Mar 2028−$0.27
Dec 2027−$0.54
Sep 2027−$0.66
Jun 2027−$0.70
Mar 2027−$0.80
Dec 2026−$0.78
Nov 2026−$0.68
Aug 2026−$0.68−$0.63+7.1%
May 2026−$0.75−$0.66+12.0%
Mar 2026−$0.85−$0.80+5.3%
Nov 2025−$0.97−$0.85+12.4%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Sep 2023
Jun 2023
Mar 2023
Dec 2022

The latest year is open to everyone — the 11 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2028$0.54$0
Sep 2028$0.24$0
Jun 2028−$0.10$0
Mar 2028−$0.27$0
Dec 2027−$0.54$18.9M
Sep 2027−$0.66$4.6M
Jun 2027−$0.70$2.0M
Mar 2027−$0.80$1.0M
Dec 2026−$0.78$0
Nov 11, 2026−$0.68$0
Aug 12, 2026−$0.68−$0.63+7.1%+0.4%
May 12, 2026−$0.75−$0.66+12.0%−1.1%
Mar 26, 2026−$0.85−$0.80+5.3%+2.0%
Nov 12, 2025−$0.97−$0.85+12.4%+4.7%
Aug 12, 2025
May 13, 2025
Mar 27, 2025
Nov 13, 2024
Aug 12, 2024
May 14, 2024
Mar 26, 2024
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022

The latest year is open to everyone — the 11 quarters behind it read with an account.